Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of IPH6501 in Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma
2023-506976-28-00Phase 2Completed
- Sponsor
- Innate Pharma
- Start
- Mar 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of IPH6501 in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and 4 more, sponsored by Innate Pharma. Primary endpoints: Maximum tolerated dose or highest tested dose and Safety and tolerability of IPH6501. Started Mar 2024; status: completed.
02
Drugs
IPH6501
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)large-cell lymphomaprimary mediastinal large B-cell lymphoma (PMBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on 2023-506976-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506976-28-00.